TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, announced financial results for the first quarter ending March 31, 2020, and provided a business update.
May 13, 2020
· 7 min read